Rocket One (RKTO) Non Operating Investment Income (2020 - 2023)
Rocket One's (RKTO) quarterly Non Operating Investment Income came in at -$24567.0 in Q4 2023, up 93.42% year-over-year from -$12701.2 in Q4 2022, and up 85.2% quarter-over-quarter from -$165950.0 in Q2 2023.
Powered by 
Analysis
Rocket One (RKTO) Non Operating Investment Income (2020 - 2023) Analysis & Trends
Rocket One has disclosed Non Operating Investment Income across 4 years of filings, most recently posting -$24567.0 for Q4 2023.
- In Q4 2023, Non Operating Investment Income rose 93.42% year-over-year to -$24567.0; the TTM figure through Dec 2023 stood at -$209320.0 (up 61.32% YoY), while the FY2023 annual figure was -$209320.0, up 63.13% from the prior year.
- Non Operating Investment Income came in at -$24567.0 for Q4 2023 at Rocket One, up from -$165950.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $33330.0 in Q1 2021 to a low of -$373513.0 in Q4 2022.
- Average Non Operating Investment Income over 4 years is -$65562.6, with a median of -$21685.0 recorded in 2023.
- The largest YoY upside for Non Operating Investment Income was 581.32% in 2021 against a maximum downside of 1122.2% in 2021.
- Over 4 years, Non Operating Investment Income stood at $9883.0 in 2020, then tumbled by 1122.2% to -$101024.0 in 2021, then plunged by 269.73% to -$373513.0 in 2022, then surged by 93.42% to -$24567.0 in 2023.
- Per Business Quant data, the three most recent Non Operating Investment Income figures were -$24567.0 in Q4 2023, -$165950.0 in Q2 2023, and -$18803.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | 36.64 Mn |
| 10 | Rocket One | 13.80 Mn | 5.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -24,567.00 |
| Jun 30, 2023 | -165,950.00 |
| Mar 31, 2023 | -18,803.00 |
| Dec 31, 2022 | -373,513.00 |
| Sep 30, 2022 | 26,572.00 |
| Jun 30, 2022 | -216,127.00 |
| Mar 31, 2022 | 21,949.00 |
| Dec 31, 2021 | -101,024.00 |
| Sep 30, 2021 | -41,214.00 |
| Jun 30, 2021 | -57,352.00 |
| Mar 31, 2021 | 33,330.00 |
| Dec 31, 2020 | 9,883.00 |
| Sep 30, 2020 | -15,952.00 |
| Mar 31, 2020 | 4,892.00 |